|
V3471
|
BMS-066 |
914946-88-6 |
BMS-066 is a novel and potent tricyclic pseudokinase inhibitors of IKKβ/Tyk2withIC50sof 9 nM and 72 nM, respectively. |
|
V3516
|
BMS-346567 |
953807-31-3 |
BMS-346567, an analog of Sparsentan, is a novel, potent and selective dual angiotensin II and endothelin A receptor antagonist. |
|
V2070
|
BMS-37 |
1675202-20-6 |
BMS-37 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 protein protein interaction with IC50 value in the range of 6-100 nM in cell free assays. |
|
V2110
|
BMS-751324 |
948842-66-8 |
BMS-751324 is a novel prodrug of BMS-582949 (also known as PS540446) which is a potent and highly selective p38 mitogen-activated protein kinase (p38 MAPK) inhibitor with IC50 of 13nM and is currently in phase II clinical trials for the treatment of rheumatoid arthritis. |
|
V3468
|
BMS-819881 |
1197420-05-5 |
BMS-819881 is a novel and potent antagonist of MCHR1 (Melanin concentrating hormone receptor 1) with minimal hERG activity. |
|
V3469
|
BMS-830216 |
1197420-06-6 |
BMS-830216 isa prodrug of BMS-819881 which is a novel and potent antagonist of MCHR1 (Melanin concentrating hormone receptor 1) with minimal hERG activity. |
|
V3464
|
BMS-986163 |
1801151-09-6 |
BMS-986163, a novel water-soluble phosphate prodrug ofBMS-986169designed for IV administration, is a negative allosteric modulator ofGluN2B which is aN-methyl-d-aspartate receptor subtype. |
|
V3465
|
BMS-986169 |
1801151-08-5 |
BMS-986169 is a novel and potent negative allosteric modulator ofGluN2B which is aN-methyl-d-aspartate receptor subtype. |
|
V3498
|
BPN14770 |
1606975-12-5 |
BPN14770 is a novel and potent allosteric modulator of phosphodiesterase-4 (PDE4) with IC50 values of 8 and 130 nM for human and mouse PDE4D, respectively. |
|
V3946
|
CA-327 |
|
CA-327 is a novel potent, orally available, small molecule and dual inhibitor of TIM3 and PD-L1 with potential anticancer activities. |
|
V3631
|
Calyculin A |
101932-71-2 |
Calyculin A is a novel, potent, selective and cell-permeable inhibitor of protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A) withIC50s of 0.5 to 1 nM. |
|
V3889
|
Cannabidiol |
13956-29-1 |
NOT AVAILABLE (CONTROLLED SUBSTANCE; Schedule I drugs under the Controlled Substances Act. |
|
V3473
|
Cariprazine sulfate |
|
Cariprazine (formerly known as MP-214 and RGH-188) is a novel and potent antipsychotic drug candidate that is in late-stage clinical development for the treatment of schizophrenia, as well as for bipolar disorder (manic/mixed and depressive episodes), and as an adjunctive agent for the treatment of major depressive disorder. |
|
V4372
|
CETUXIMAB |
205923-56-4 |
Cetuximab (C225; C 225; C-225; Erbitux) is a potent and specific chimeric monoclonal antibody approved for cancer treatment. |
|
V3571
|
dBRD9 |
2170679-45-3 |
dBRD9 (dBRD-9) is a novel and potent PROTAC degrader of the BRD9 bromodomain and the cereblon E3 ubiquitin ligase complex with anticancer activity. |
|
V2161
|
Desciclovir |
84408-37-7 |
Desciclovir is a precursor of acyclovir (ACV), a potent and orally bioactive antiherpetic molecule. |
|
V4390
|
DFMTI |
864864-86-8 |
DFMTI is a novel compound that can completely block the rmGlu1 L757V glutamate response by acting as anovel mGlu₁ negative allosteric modulator. |
|
V3960
|
DIETHYL PYIMDC |
1821370-64-2 |
Diethyl pyimDC is a novel inhibitor of human CP4H1 (collagen prolyl 4-hydroxylase 1). |
|
V2612
|
Diethylmaleate |
141-05-9 |
Diethylmaleate is the diethyl ester of maleic acid and a glutathione-depleting compound that inhibits NFkB. |
|
V3228
|
DORA-22 |
1088991-95-0 |
DORA-22 is a novel, potent and selective dual orexin receptor antagonist that may be useful for insomnia andAD-relevant symptoms. |